Baidu
map

SCIENCE:肿瘤转移至淋巴结需要YAP依赖性代谢适应

2019-02-10 海北 MedSci原创

在癌症患者中,肿瘤向前哨淋巴结(LN)的转移预测着疾病的进展,并且经常指导治疗决策。

在癌症患者中,肿瘤向前哨淋巴结(LN)的转移预测着疾病的进展,并且经常指导治疗决策。

至今为止,我们关于肿瘤LN转移的潜在机制知之甚少。最近,通过使用小鼠原发性和LN转移性肿瘤的比较转录组学和代谢组学分析,研究人员发现,LN转移需要肿瘤细胞经历向脂肪酸氧化的代谢转变(FAO)。转录共激活因子相关蛋白(YAP)在LN转移性肿瘤中被选择性激活,导致FAO信号传导途径中基因的上调。

FAO的药理学抑制或YAP的遗传消除抑制了小鼠肿瘤的LN转移。几种生物活性胆汁酸在转移性LN中积累到高水平,并且这些胆汁酸可能通过核维生素D受体激活肿瘤细胞中的YAP

因此,该结果显示,抑制FAOYAP可能可以作为减轻肿瘤转移至LN的潜在治疗策略。


原始出处:

Choong-kun Lee et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. SCIENCE, 2019; doi: 10.1126/science.aav0173


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081913, encodeId=700820819131e, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Thu Jan 16 00:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291646, encodeId=a32b1291646f2, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293060, encodeId=9f5a129306084, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375919, encodeId=571a13e5919e8, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
    2020-01-16 gujh
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081913, encodeId=700820819131e, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Thu Jan 16 00:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291646, encodeId=a32b1291646f2, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293060, encodeId=9f5a129306084, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375919, encodeId=571a13e5919e8, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081913, encodeId=700820819131e, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Thu Jan 16 00:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291646, encodeId=a32b1291646f2, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293060, encodeId=9f5a129306084, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375919, encodeId=571a13e5919e8, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
    2019-02-12 sodoo
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081913, encodeId=700820819131e, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Thu Jan 16 00:57:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291646, encodeId=a32b1291646f2, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293060, encodeId=9f5a129306084, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375919, encodeId=571a13e5919e8, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Feb 12 05:57:00 CST 2019, time=2019-02-12, status=1, ipAttribution=)]
    2019-02-12 jichang

相关资讯

2018年中国肿瘤临床试验蓝皮书

1. 前言 本蓝皮书纳入统计的肿瘤试验全部来源于“药物临床试验登记与信息公示平台”(http://www.chinadrugtrials.org.cn/eap/main),时间以登记网站上“首次公示信息日期”作为统计时间节点,有些试验可能早就结束,但首次公示信息日期是2018年,也纳入统计;有些试验招募的是健康受试者,则不在统计范围以内。 2.

中年女性,右髋部肿瘤,请诊断!

患者2年前因左髋骨折摄片时偶然发现右髋部肿瘤,患者定期检测右髋部情况。1月前,患者右髋出现隐痛,能忍受,左髋亦有痛疼感。

Lancet oncol:Tisotumab vedotin可安全治疗多种固体肿瘤

Tisotumab vedotin是一种针对在多种实体肿瘤中均有表达、与临床预后差相关的组织因子的首个人体内的抗体-药物偶联物。现研究人员在表达组织因子的局部晚期或转移性固体肿瘤患者的混合人群中评估tisotumab vedotin的安全性、耐受性、药代动力学和抗肿瘤活性。研究人员在USA和欧洲的21个中心开展一个I-II期的开放性、剂量递增性和剂量扩展性研究(InovaTV201),招募年满18

开年大吉:张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变:肿瘤学I期临床试验年度报告》

长期以来,冗长的药品审评流程导致很多新药在中国大陆迟迟无法上市,患者面临无药可用的困境,这一现象在业内被称为“药滞(Drug-lag)”。2017年以来,国家实施了一系列药品审评、监管制度改革,旨在彻底扭转这一困局。近年来,抗肿瘤药物研发模式也发生了巨大变革,“无缝(seamless)设计”逐渐取代传统的三阶段药物开发模式。I期临床试验从原来的安全性试验转变为机制验证性(proof-of-mech

NATURE:中性粒细胞可护送循环肿瘤细胞

研究人员认为,更好地理解和定义癌细胞和免疫细胞之间相互作用的特征对于新癌症疗法的开发是至关重要的。

Baidu
map
Baidu
map
Baidu
map